Evidence map›Paper›PMID 28652245›Full record

ArticleCancer research2017

Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function.

Haijiao Zhang, Sophie Means, Anna Reister Schultz, Kevin Watanabe-Smith, Bruno C Medeiros, Daniel Bottomly, Beth Wilmot, Shannon K McWeeney, Tim Kükenshöner, Oliver Hantschel and 1 more

Open access · greenAbstract readCase Reports
In one paragraph

Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Haematologica · 2025
    Article
  2. Article
  3. Review
  4. Multiplex, multimodal mapping of variant effects in secreted proteins.bioRxiv : the preprint server for biology · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Haijiao ZhangDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University Knight Cancer Institute, Portland, Oregon.
Sophie MeansDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University Knight Cancer Institute, Portland, Oregon.
Anna Reister SchultzDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University Knight Cancer Institute, Portland, Oregon.
Kevin Watanabe-SmithDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University Knight Cancer Institute, Portland, Oregon.
Bruno C MedeirosDepartment of Medicine, Stanford University School of Medicine, Stanford, California.
Daniel BottomlyDivision of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University Knight Cancer Institute, Portland, Oregon.
Beth WilmotDivision of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University Knight Cancer Institute, Portland, Oregon.
Shannon K McWeeneyDivision of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University Knight Cancer Institute, Portland, Oregon.
Tim KükenshönerSwiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Oliver HantschelSwiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Jeffrey W TynerDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University Knight Cancer Institute, Portland, Oregon. tynerj@ohsu.edu.
Oregon Health & Science University · USÉcole Polytechnique Fédérale de Lausanne · CHStanford Medicine · US

Funding

Pathogenetic Mechanism and Clinical Targeting of CSF3R-Driven CancerR01CA183974 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI TYNER, JEFFREY WALLACE · 2014 to 2018
$1.6M
ROR1 as a Therapeutic Target in Acute Lymphoblastic LeukemiaR00CA151457 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI TYNER, JEFFREY WALLACE · 2012 to 2014
$723k
NCI NIH HHS R00 CA151457NCI NIH HHS R01 CA183974
6 · The paper itself

Abstract

Exclusive of membrane-proximal mutations seen commonly in chronic neutrophilic leukemia (e.g., T618I), functionally defective mutations in the extracellular domain of the G-CSF receptor (CSF3R) have been reported only in severe congenital and idiopathic neutropenia patients. Here, we describe the first activating mutation in the fibronectin-like type III domain of the extracellular region of CSF3R (W341C) in a leukemia patient. This mutation transformed cells via cysteine-mediated intermolecular disulfide bonds, leading to receptor dimerization. Interestingly, a CSF3R cytoplasmic truncation mutation (W791X) found on the same allele as the extracellular mutation and the expansion of the compound mutation was associated with increased leukocytosis and disease progression of the patient. Notably, the primary patient sample and cells transformed by W341C and W341C/W791X exhibited sensitivity to JAK inhibitors. We further showed that disruption of original cysteine pairs in the CSF3R extracellular domain resulted in either gain- or loss-of-function changes, part of which was attributable to cysteine-mediated dimer formation. This, therefore, represents the first characterization of unpaired cysteines that mediate both gain- and loss-of-function phenotypes. Overall, our results show the structural and functional importance of conserved extracellular cysteine pairs in CSF3R and suggest the necessity for broader screening of CSF3R extracellular domain in leukemia patients.

Indexed as

Mutation, MissenseAgedAnimalsCysteineExomeFemaleHEK293 CellsHumansLeukemia, Myeloid, AcuteMiceNIH 3T3 CellsPhenotypeReceptors, Colony-Stimulating FactorCSF3R protein, humanCysteineReceptors, Colony-Stimulating Factor

Identifiers

PMID28652245
PMCPMC5763920
OpenAlexW2628318834

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.